

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Thomas V. Magee, et al.

Examiner: To Be Assigned

APPLICATION NO.: To Be Assigned

FILING DATE: To Be Assigned

:Group Art Unit: To Be Assigned

TITLE: Nicotinamide Acids, Amides, and Their Mimetics :

Active As Inhibitors of PDE4 Isozymes

Commissioner for Patents

PO Box 1450

Alexandria, VA 22313-1450

Sir:

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97 ET SEQ.

Applicant(s) herein make(s) available to the U.S. Patent and Trademark Office a copy of PTO-FB-A820 which lists the references cited by the applicant(s), copies of which are enclosed.

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of the above-identified application in accord with 37 C.F.R. § 1.104(a). It is believed the Examiner will concur with applicant's belief that the subject matter presently claimed is neither anticipated nor rendered obvious by the foregoing references.

It is requested that the references listed on the attached form PTO-FB-A820 be included in the "References Cited" portion of any patent issuing from this application (M.P.E.P. § 1302.12).

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Date:

February 17, 2004

Robert T. Ronau
Robert T. Ronau

Attorney for Applicant(s)

Reg. No. 36,257

Pfizer Inc.
Patent Department, Box 8260-1611
Eastern Point Road
Groton, CT 06340
(860) 441-5910

EXPRESS MAIL NO. 95071824859 US

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> Page 1 of 3									ATTY. DOCKET NO. PC11895B			SERIAL NO. To Be Assigned		
APPLICANT Thomas V. Magee, et. al.									FILING DATE To Be Assigned			GROUP To Be Assigned		

U.S. PATENT DOCUMENTS													
EXAMINER INITIAL	US	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US	4	1	5	7	3	9	5	5 Jun 79	Hitzel, Volker, et. al.	424	266	
	US	4	1	8	1	6	5	8	1 Jan 80	Hitzel, Volker, et. al.	424	266	
	US	4	8	6	1	8	9	1	29 Aug 89	Saccomano, Nicholas A., et al	546	194	
	US	4	6	9	2	1	8	5	8 Sep 87	Michaely, William J.	71	94	
	US	5	5	5	2	4	3	8	3 Sep 96	Christensen, Siegfried B. IV	514	520	
	US	5	6	0	2	1	5	7	11 Feb 97	Christensen, Siegfried B. IV	514	362	
	US	5	6	1	4	5	4	0	25 Mar 97	Christensen, Siegfried B. IV	514	362	
	US	5	8	6	3	9	2	6	26 Jan 99	Christensen, Siegfried B. IV, et al	514	277	
	US	5	9	2	2	5	5	7	13 Jul 99	Pon, Douglas J.	435	21	
	US	6	3	8	0	2	1	8	30 Apr 02	Marfat, Anthony, et. al.	514	326	

FOREIGN PATENT DOCUMENTS														
DOCUMENT NUMBER									DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
													YES	NO
	WO	9	8	1	8	7	9	6	7 May 98	International	C07D	471/04		
	WO	9	8	4	5	2	6	8	15 Oct 98	International	C07D	213/82		
	WO	9	9	1	8	7	9	3	22 Apr 99	International	A01N	43/38		
	WO	9	5	0	0	1	3	9	5 Jan 95	International	A61K	31/275		
	WO	9	9	2	0	6	2	5	29 Apr 99	International	C07D	473/16		
	WO	9	9	2	0	2	8	0	29 Apr 99	International	A61K	31/52		
	WO	0	1	5	7	0	2	5	9 Aug 01	International	C07D	405/12		
	WO	0	1	5	7	0	3	6	9 Aug 01	International	C07D	413/12		
	GB	2	3	2	7	6	7	5	3 Feb 99	Great Britain	C07D	213/82		
	EP	0	0	2	3	5	6	9	22 Jun 83	EPO	C07D	295/14		
	EP	0	5	5	0	9	0	0	28 Dec 92	EPO	A01N	43/40		X
	EP	0	5	0	0	9	8	9	9 Dec 98	EPO	C07K	5/06		
	EP	0	6	6	1	2	7	4	5 Jul 95	EPO	C07D	237/14		
	JP	7	3	0	4	7	7	5		Japanese				X
	FR	2	1	4	0	7	7	2		French	C07D	29/00		X

EXPRESS MAIL NO. EU 27182485905

4/97, !disclos, 1/3

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Page 2 of 3		ATTY. DOCKET NO. PC11895B	SERIAL NO. To Be Assigned
		APPLICANT Thomas V. Magee, et. al.	
		FILING DATE To Be Assigned	GROUP To Be Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
		Trophy, Theodore J. et al, "Phosphodiesterase IV Inhibitors as Therapy for Eosinophil-induced Lung Injury in Asthma," Environmental Health Perspectives, Vol. 102 Suppl. 10, Dec. 1994, pp 79-84,	
		Duplantier, Allen J., et al., "Biarylcarboxylic Acids and -amides: Inhibition of Phosphodiesterase Type IV versus [³ H]Rolipram Binding Activity and Their Relationship to Emetic Behavior in the Ferret, Journal of Medicinal Chemistry," 1996, Vol. 39, No. 1, pp 120-125	
		Schneider, Herbert H, et al, "Discriminative Stimulus Properties of the Stereoisomers of the Phosphodiesterase Inhibitor Rolipram," Pharmacology Biochemistry and Behavior, Vol. 50, No. 2, 1995, pp. 211-217	
		Banner, Katherine H., et. al., "Acute versus chronic administration of phosphodiesterase inhibitors on allergen-induced pulmonary cell influx in sensitized guinea-pigs," British Journal of Pharmacology, 114, 1995, pp. 93-98	
		Barnette, Mary S., et. al., "The Ability of Phosphodiesterase IV Inhibitors to Suppress Superoxide Production in Guinea Pig Eosinophils Is Correlated with Inhibition of Phosphodiesterase IV Catalytic Activity," The Journal of Pharmacology and Experimental Therapeutics, 273, 1995 pp. 674-679	
		Wright, Kathryn, F., et al., "Differential in vivo and in vitro bronchorelaxant activities of CP-80,633, a selective phosphodiesterase 4 inhibitor," Can. J. Physiol. Pharmacol. 75, 1997, pp.1001-1008	
		Manabe, Haruhiko, "Anti-inflammatory and Bronchodilator Properties of KF19514, a Phosphodiesterase 4 and 1 Inhibitor," European Journal of Pharmacology, 332, 1997, pp. 97-107	
		Ukita, Tatsuzo, et. al., "Novel, Potent, and Selective Phosphodiesterase-4 Inhibitors as Antiasthmatic Agents: Synthesis and Biological Activities of a Series of 1-Pyridynaphthalene Derivatives, J. Med. Chem, 48, 1999, pp. 1088-1099	
		Compton, CH, et. al., "The Efficacy of Ariflo™ (SB 207499, A Second Generation, Oral PDE4 Inhibitor, In Patients with COPD, Am. J. Respir. Crit. Care Med., 159, 1999	
		Leeman, Marc M.D., et. al., "Reduction in Pulmonary Hypertension and in Airway Resistances by Enoximone (MDL 17,043) in Decompensated COPD," Chest, 91, 1987, pp. 662-6	
		Rabe, K.F., et. al., "Identification of PDE Isozymes in Human Pulmonary Artery and Effect of Selective PDE Inhibitors," Am. J. Physiol, 266 (LCMP 10), 1994, pp. L536-L543	
		Hughes, Bernadette, et. al., "PDE 4 inhibitors: the use of molecular cloning in the design and development of novel drugs, Drug Discovery Today, Science Direct, 2(3), 1997 pp. 89-101	
		Banner, K.H., et. al., "The Effect of Selective Phosphodiesterase Inhibitors in Comparison with other Anti-asthma Drugs on Allergen-induced Eosinophilia in Guinea-pig Airways," Pulmonary Pharmacology, 8, 1995, pp. 37-42	
		Raeburn, David, et.al., "Anti-inflammatory and bronchodilator properties of RP 73401, a novel and selective phosphodiesterase typed IV inhibitor," Br. J. Pharmacol., 113, 1994, pp. 1423-1431	
		Karlsson, J.A., et. al., "Anti-Inflammatory Effects of the Novel Phosphodiesterase IV Inhibitor RP 73401," Int. Arch Allergy Immunol, 107, 1995, pp. 425-426	
		Escott, K.J., et. al., "Pharmacological Profiling of Phosphodiesterase, 4 (PDE4) Inhibitors and Analysis of the Therapeutic Ratio in Rats and Dogs, Br. J. Pharmacol, 123 (Proc suppl.) 1998 40P	
		Landells, L.J., et. al., "Oral Administration of the Phosphodiesterase (PDE) 4 Inhibitor, V11294A Inhibits Ex-Vivo Agonist-induced Cell Activation," Eur. Resp. J., 12 (Suppl. 28), 362s, 1998, P2393	
		Gale, D.D., et. al., "Pharmacodynamic-Pharmacokinetic (PD/PK) Profile of the Phosphodiesterase (PDE)4 Inhibitor, V11294A, in Human Volunteers," Am. J. Respir. Crit Care Med., 159, A611, 1999, pp A108	
		Montana, J., et. al., "Activity of D4418, A Novel Phosphodiesterase 4 (PDE4) Inhibitor, Effects in Cellular and Animal Models of Asthma and Early Clinical Studies," Am. J. Respir. Crit., Care Med., 159, A108, 1999, pp A624	
		Cavalla, D., et. al., "Activity of V11294A, A Novel Phosphodiesterase 4 (PDE4) Inhibitor, In Cellular and Animal Models of Asthma," Am. J. Respir. Crit. Care Med. 155, 1997, pp A660	
		Pascal, Y., et. al., "Synthesis and Structure,-activity Relationships of 4-oxo-1 phey-3,4,5,7-Tetrahydro-[1,4]Diazepino[6,7,1-H]Indolines: Novel PDE4 Inhibitors," 215 th ACS, MEDI, 50, 1998	
		Burnouf, C., et. al., "Pharmacology of the Novel Phosphodiesterase Type 4 Inhibitor, CI-1018," 215 th ACS, MEDL 008, 1998	

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> Page 3 of 3		ATTY. DOCKET NO. PC11895B APPLICANT Thomas V. Magee, et. al. FILING DATE To Be Assigned	SERIAL NO. To Be Assigned GROUP To Be Assigned
		Mueller, George W., et. al., "N-Phthaloyl-β- Aryl- β- Amino Derivatives Potent TNF-α And PDE4 Inhibitors, MEDI, 299, 1999	
		Mueller, George W., et. al., "Thalidomide Analogs and PDE4 Inhibition," Bioorganic & Medicinal Chemistry Letters," 8, 1998 pp. 2669-2674	
		Takayama, K., "Synthetic Studies on Selective Type IV Phosphodiesterase (PDE IV) Inhibitors," MEDI 245, 1997	
		Gordon, T., et. al., "Anti-Inflammatory Effects of a PDE4 Inhibitor in a Rat Model of Chronic Bronchitis," Am. J. Respir. Crit. Care Med., 159, A33, 1999	
		Perrier, Helene, et. al., "Substituted Furans as Inhibitors of the PDE4 Enzyme," Bioorganic & Medicinal Chemistry Letters 9, 1999, pp. 323-326	
		Groneberg, Robert D., et. al., "Dual Inhibition of Phosphodiesterase 4 and Matrix Metalloproteinases by an (Arylsulfonyl)hydroxamic Acid Template," Journal of Medicinal Chemistry, 1999, Vol. 42, No. 4, pp. 541-544	
		Fujimura, Masaki, et. al. Bronchoprotective Effects of KF-19514 and Cilostazol in Guinea Pigs In Vivo," European Journal of Pharmacology, 327, 1997, pp. 57-63	
		Manabe, Haruhiko, et. al., "KF19514, a Phosphodiesterase 4 and 1 Inhibitor, Inhibits PAF-Induced Lung Inflammatory Responses by Inhaled Administration in Guinea Pigs," International Archives of Allergy-Immunology, 1997, 114, pp. 389-399	
		Suzuki, Fumio, et. al., "New Bronchodilators, 3. Imidazo[4,5-c][1,8]naphthyridin-4(5H)-ones," Journal of Medicinal Chemistry, 1992, Vol., 35, No. 26, pp. 4866-4874	
		Matsuura, Akihiro, et. al., "Substituted 1,8-Naphthyridin-2(1H)-ones as Selective Phosphodiesterase IV Inhibitors," Biol. Pharm. Bull. Vol. 17(4), 1994, pp. 498-503	
		Manabe, Haruhiko, et. al., "Pharmacological properties of a New Bronchodilator, KF17625," Jpn. J. Pharmacol., 58 (Suppl 1), 1992 pp. 238	
		Montana, John G., et. al., "PDE4 Inhibitors: New Xanthine Analogues," Bioorganic & Medicinal Chemistry Letters 8, 1998, pp. 2925-2930	
		Merz, Karl-Heinz, et. al., "Synthesis of 7-Benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine and Novel Derivatives Free of Positional Isomers. Potent Inhibitors of cAMP-Specific Phosphodiesterase and of Malignant Tumor Cell Growth," Journal of Medicinal Chemistry, Vol. 41, No. 24, 1998, pp. 4733-4743	
		Danhaive, P., et. al., "UCB29936, A Selective Phosphodiesterase Type IV Inhibitor; Therapeutic Potential In Endotoxic Shock," Am. J. Respir. Crit. Care Med., 159, A611, 1999	
		Tian, Gaochao, et. al., "Dual Inhibition of Human Type 4 Phosphodiesterase Isostates by (R*,R*)-(±)-Methyl 3-Acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3-methyl-1-pyrrolidinecarboxylate," Biochemistry, 37(19), 1998 pp. 6894-6904	
		Norman, Peter, "PDE4 Inhibitors 1999," Exp. Opin. Ther. Patents 9(8) 1999, pp. 1101-1118	
		Dyke, Hazel J. & Montana, John G., "The Therapeutic Potential of PDE4 Inhibitors," Expert Opinion on Investigational Drugs, 8(9), 1999, pp. 1301-1325	
		XP-002066969, Vinivk, Fredric J., et. al., "Nicotinamide Ethers: Novel Inhibitors of Calcium-Independent Phosphodiesterase and [3H]Rolipram Binding," Journal of Medicinal Chemistry, Vol. 34, No. 1., 1991, pp. 86-89	
		Pruniaux, M.P., et. al., "The novel phosphodiesterase 4 inhibitor CI-1018 inhibits antigen-induced lung eosinophilia in sensitized brown-norway rats – comparison with rolipram," Mediators of Inflammation, Vol. 8, Supplement 1, 1999, S-04-6, pp. S10	
EXAMINER		DATE CONSIDERED	
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			